Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) has shared an update.
AIM Vaccine Co., Ltd. announced the successful passing of all proposed resolutions during its 2024 Annual General Meeting held on May 20, 2025. Notably, the company approved amendments to its Articles of Association, resulting in the dissolution of its Supervisory Committee in favor of establishing an audit committee, aligning with PRC Company Law. This strategic shift may enhance governance efficiency and align with industry standards, potentially impacting the company’s operational oversight and stakeholder confidence.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry with a focus on vaccine development and production.
Average Trading Volume: 4,400,526
Technical Sentiment Signal: Sell
Learn more about 6660 stock on TipRanks’ Stock Analysis page.